Navigating the new Clinical Trial Regulation with DIA
November 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, dia, drugs, pharma, pharmaceutical
For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will …
Boehringer celebrates EU approval of Humira biosimilar
November 14, 2017Manufacturing and Production, Sales and Marketing Boehringer, Boehringer Ingelheim, Cyltezo, EU, Europe, European Commission, Humira, biosimilar
Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …
Novartis targets specific patient population with strong Ilaris Phase 3 data
November 14, 2017Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma
Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …
Pfizer creates COO role so CEO Ian Read can focus on deal-making
November 14, 2017Manufacturing and Production, Sales and Marketing Image Credit: Pfizer
In a sizeable shake-up of its business operations, Pfizer has promoted Albert Bourla (pictured) to the role of Chief Operating …
Ex-Lilly exec Trump’s nominee for health secretary
November 14, 2017Manufacturing and Production, Medical Communications Alex Azar, Donald Trump, biotech, drugs, pharma, pharmaceutical
Alex Azar is officially President Trump’s nominee for the position as head of the Health and Human Services (HHS) agency, …
Hansa Medical mourns death of CEO
November 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hansa Medical, pharma
Swedish biopharma firm Hansa Medical broke tragic and unexpected news in November when it announced the death of its CEO …
EMA Headquarters: There’s no place like home
November 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, biotech, brexit, drugs, pharma, pharmaceutical
With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 …
Mylan to withdraw from Tel Aviv Stock Exchange
November 13, 2017Sales and Marketing Mylan, TASE, pharma
US drug maker Mylan has announced its intention to withdraw from the Tel Aviv Stock Exchange (TASE), ending its involvement …
Novartis touts longer-lasting AMD rival to Eylea
November 13, 2017Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical
Novartis posted strong results for its wet age-related macular degeneration (AMD) drug, by showing superiority against Eylea in Phase 3 …
EMA recommends approval of Roche’s Ocrevus in relapsing forms of multiple sclerosis
November 13, 2017Sales and Marketing MS, Ocrevus, Roche, multiple sclerosis, pharma
Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …
UK rates of obesity increased by 92% over two decades
November 13, 2017Research and Development, Sales and Marketing OECD, biotech, drugs, obesity, pharma, pharmaceutical
A recent report by the OECD shares concerns that the UK’s overall health looks set to face a crisis due …
Nigerian agency strongly contests that 70% of drugs are fake
November 13, 2017Manufacturing and Production, Sales and Marketing Nigeria, biotech, drugs, pharma, pharmaceutical, pwC
Nigeria’s drug regulatory body has fiercely countered claims made by Chief Economist of PwC in West Africa, Andrew Nevin, that …
Top Ten most popular articles on Pharmafile.com this week
November 10, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top ten
Friday again, and we bring you the most read articles on our site this week – one of which was …
Hep-B vaccine four-year battle for FDA approval is finally won
November 10, 2017Medical Communications, Sales and Marketing biotech, drugs, dynavax, hepatitis B, pharma, pharmaceutical
Dynavax had said it was the last throw of the dice for its hepatitis B vaccine, Hepislav-B – the data …
Sanofi signs $805 million deal for MS drug
November 10, 2017Medical Communications, Sales and Marketing Principia Biopharma, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi has decided to build its pipeline in neurological disorders with the agreement to develop Principia Biopharma’s BTK inhibitor candidate …
Breast cancer recurrence can occur up to 20 years after treatment, report shows
November 10, 2017Medical Communications, Research and Development Cancer, breast cancer, pharma, tamoxifen
New findings from the Early Breast Cancer Trialists’ Collaborative Group have demonstrated that oestrogen receptor-positive (ER-positive) breast cancer is able …
Sage scores good but not great P3 postpartum depression drug results
November 10, 2017Medical Communications, Research and Development Sage Therapeutics, biotech, drugs, pharma, pharmaceutical
Sage Therapeutics share price soared 50% on the release that its two Phase 3 trials of brexanolone showed statistically significant …
Recipharm Interim report January – September 2017
November 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm
Interim report January – September 2017 July – September 2017
Recipharm to end operations in two facilities in Sweden
November 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm
Recipharm today announces that it will initiate a process with the intention of discontinuing manufacturing operations at its facilities in …
NHS England seals access deals with big pharma for breast cancer and MS
November 9, 2017Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
